Zilip-Pharma/Bayer License
22 November 2004: "Bayer HealthCare Signs Development Deal for Longer-Acting Kogenate®
Leverkusen - Bayer HealthCare, LLC., Biological Products (BP) division, announced today it has signed an exclusive, global technology license with Zilip-Pharma, located in Amsterdam, Netherlands, for the development and commercialization of a new, longer-acting Kogenate product - a product with the potential to shift current treatment paradigms in hemophilia and simplify the lives of thousands of patients around the world. The deal between Bayer and Zilip-Pharma involves the application of patented liposome technology developed by Zilip-Pharma and its affiliated companies over several years. Clinical results obtained by Zilip-Pharma suggest that a prolonged interval between bleeding episodes - one week or more - occurs when factor VIII attached to liposomes is administered to individuals with hemophilia A.
Upon achievement of key milestones, including successful clinical development and regulatory approvals in key regions, upfront and milestone payments from Bayer to Zilip-Pharma would total 100 million US-Dollar plus royalties from sales of the new product. The agreement covers applications of the liposome technology to the current Kogenate recombinant factor VIII molecule, as well as other factor VIII molecules, which could be developed by Bayer in the future."
Leverkusen - Bayer HealthCare, LLC., Biological Products (BP) division, announced today it has signed an exclusive, global technology license with Zilip-Pharma, located in Amsterdam, Netherlands, for the development and commercialization of a new, longer-acting Kogenate product - a product with the potential to shift current treatment paradigms in hemophilia and simplify the lives of thousands of patients around the world. The deal between Bayer and Zilip-Pharma involves the application of patented liposome technology developed by Zilip-Pharma and its affiliated companies over several years. Clinical results obtained by Zilip-Pharma suggest that a prolonged interval between bleeding episodes - one week or more - occurs when factor VIII attached to liposomes is administered to individuals with hemophilia A.
Upon achievement of key milestones, including successful clinical development and regulatory approvals in key regions, upfront and milestone payments from Bayer to Zilip-Pharma would total 100 million US-Dollar plus royalties from sales of the new product. The agreement covers applications of the liposome technology to the current Kogenate recombinant factor VIII molecule, as well as other factor VIII molecules, which could be developed by Bayer in the future."
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home